Pharmacoeconomics: theory and practice
№4, 2016, Vol.4
Melanoma is a malignant tumor that develops from transformed melanocytes, located mainly in the skin. According to Russian statistics, the incidence of melanoma in 2014 was 9,390 new cases. In 2004-2014, melanoma prevalence rate per 100,000 population increased on average by 4.2% per year. High prevalence of melanoma and frequent poor prognosis necessitate search of innovative treatment methods and use of high-tech drugs. The unmet need for oncology therapies is substantial. The introduction of innovative, highcost treatments, coupled with mounting budgetary pressures, will necessitate value trade-offs across cancer types. Defining value will be critical to informing decision-making. The purpose of this study was to perform relative value analysis (RVA) of the ipilimumab use in patients with metastatic melanoma among the entire group of oncology products selected for comparison. Relative value analysis (RVA) can be used to benchmark the clinical and economic value delivered by one product versus others in a broad therapeutic class, using acceptable statistical methods applied to clinical and economic measures. These are naive comparisons with no adjustment for differences in trial characteristics or patient populations. The analysis could not be consider as a substiture for ITC/NMA or more sophisticaled cost effectiveness modeling.
Hemophilia is one of the rare, socially significant, hereditary diseases drug supply of which centralized in the framework of the program “7 nosologies” at the expense of the Federal budget. According to IMS Health, in 2015 the consumption of medicinal drugs used in the treatment of hemophilia reached 11.2 billion RUB that shows an increase of 16.9% compared to 2010. The main drivers of market growth have become the primarily raising awareness of the disease and the increase in diagnosis led to growth of the patient population as a whole, as well as understanding of the need for effective and quality care that led to a rise of the prescription of the preventive therapy, in which a comparably larger consumption of the medicines for the patient leads to a significant improvement in outcomes and safety of patients. The improving of the quality of medical care is also implemented through the inclusion into the program of modern recombinant medicines, possessing the best safety profile in comparison to the medicines obtained from the plasma of donated blood. Every year the budgetary allocation for the treatment of high-cost nosology in general and for hemophilia increases, that indicates the primary focus of health aimed for improving of the quality of life of patients.
To assess the level of development of pharmacoeconomics in the Russian Federation as a branch of science analysis of pharmacoeconomic and clinical economic studies published in the scientific electronic library “eLIBRARY.RU” (RSCI) for the period from 2005 through 2015 was performed. As a result, it was determined that the number of such studies from year to year is steadily increasing. The leader among the countries who publish their researches on the platform of the scientific electronic library “eLIBRARY. RU” was Russia, the second and the third places were shared by Ukraine and Belarus, respectively. The research was carried out in 52 subjects of the Russian Federation, which is represented by 63 Universities. Leader out of them was the I.M. Sechenov First Moscow State Medical University. It turned out that most pharmacoeconomic and clinical-economic research during the specified time interval was devoted to cardiovascular, pulmonary, oncological and endocrinological diseases. As a result of analysis, it was found that among pharmacoeconomic research methods most commonly used “cost– effectiveness” analysis (45,1%). In addition, on the basis of the analyzed data of Russian science citation index and the total number of published works, the rating of the authors who conducted research in the field of pharmacoeconomics in the country.